BioIndiana
Filter News
Found 1,269 articles
-
YourEncore Launches Clinical Center of Excellence
9/10/2019
YourEncore, a strategic and technical advisory company serving clients in the life sciences and consumer goods industries, has announced the launch of its Clinical Center of Excellence (CoE).
-
When Eli Lilly and Company acquired Loxo Oncology for $8 billion, the company was gambling on several pipeline drugs in oncology.
-
Lilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer
9/9/2019
Eli Lilly and Company presented data from the LIBRETTO-001 clinical trial intended to support the registration of oral selpercatinib[1] monotherapy, also known as LOXO-292, for the treatment of RET fusion-positive non-small cell lung cancer.
-
Acacia Pharma Group plc - Interim Results for the Six Months ended 30 June 2019
9/5/2019
Acacia Pharma Group plc announces its unaudited interim results for the six-month period ended 30 June 2019.
-
Survey of Benefits Decision-Makers About the Burden of Diabetes in the Workplace Reveals Sleepless Nights, Secrets and Solutions
9/4/2019
In the silence of the night, seven out of ten benefits decision-makers at US employers are awake seeking a solution for the financial and human burden of diabetes management, according to the findings of a new survey.
-
Survey of benefits decision-makers about the burden of diabetes in the workplace reveals sleepless nights, secrets and solutions
9/4/2019
In the silence of the night, seven out of ten benefits decision-makers at US employers are awake seeking a solution for the financial and human burden of diabetes management, according to the findings of a new survey.
-
Lilly to Participate in Morgan Stanley Global Healthcare Conference - Sept. 4, 2019
9/4/2019
Eli Lilly and Company will attend the Morgan Stanley Global Healthcare Conference on Wednesday, September 11, 2019.
-
Clinical Catch-Up: August 25-30
9/3/2019
Rounding out the traditional summer months, last week had plenty of clinical trial news. Here’s a look at some of the top stories. -
New $3.75 million federal grant to train current and create future geriatrics workforce
9/3/2019
$7.2 million total funding since 2015 for more providers of age-friendly healthcare
-
BioSpace Movers & Shakers, Aug. 30
8/30/2019
Biopharma companies strengthen their leadership and boards with these appointments. -
Analysis Shows Eli Lilly’s Half-Price Humalog Generic Is Not Readily Available Across the U.S.
8/29/2019
GoodRx released an analysis that showed only 8% of fills at local pharmacies are for the Lispro Injection. The majority of insulin scripts are still being ordered for Humalog, the analysis showed. -
Drug treatment for hydrocephalus, or water on the brain, is the target of IUPUI research team
8/29/2019
Pharmaceutical partner sought to license, develop as-needed treatment that reduces cerebrospinal fluid production
-
The investigational JAK inhibitor has hit the mark in three late-stage studies, with readouts from two more late-stage trials expected later this year.
-
Polygon to Showcase PolyMed® Composite Medical Tubing for Highly Engineered Surgical Devices at MD&M Minneapolis 2019
8/26/2019
Advanced composite alternative to steel tubing showcased in Booth #2141
-
Lilly Receives U.S. FDA Approval for Taltz® (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
8/26/2019
Eli Lilly and Company announced that the U.S. Food and Drug Administration has approved Taltz® injection 80 mg/mL for the treatment of adults with active ankylosing spondylitis, also known as radiographic axial spondyloarthritis.
-
In Wake of Terminations, Pharma Leaders Decry Actions That Will Limit Collaborations with Foreign...
8/23/2019
Leaders from across the pharmaceutical industry are decrying negative actions taken by government agencies and universities against Chinese researchers in the United States. -
Eli Lilly won an arbitration hearing over accusations the Indianapolis-based company misused confidential information regarding the intellectual property of its former business partner, France-based Adocia S.A.
-
Lilly Announces Top-Line Phase 3 Results for Oral JAK Inhibitor Baricitinib, in Combination with Topical Corticosteroids in Adult Patients with Moderate to Severe Atopic Dermatitis
8/23/2019
Eli Lilly and Company (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY) announced today that baricitinib met the primary endpoint in BREEZE-AD7, the third pivotal Phase 3 trial in the BREEZE-AD program to be completed in 2019.
-
Republic Airways Nirav Shah Listed Among Top CTOs in Indianapolis
8/23/2019
Republic Airways Vice President of Information Technology Nirav Shah was recognized as one of the top CTOs in the Indianapolis area on Thursday, August 22, by the Indianapolis Business Journal and TechPoint.
-
Vibrant Life is Helping Men Wave Goodbye to Erectile Dysfunction with Cutting-edge GAINSWave® Treatment
8/23/2019
Philip C. Brittain, DO with Vibrant Life is implementing a non-invasive and drug-free solution for Erectile Dysfunction (ED).